Journal of Internal Medicine Concepts & Practice >

2022 , Vol. 17 >Issue 04: 317 - 323

DOI: https://doi.org/10.16138/j.1673-6087.2022.04.009

Original article

Effects of activin A on migration and aerobic glycolysis of gastric cancer cells

Expand
  • 1. Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Received date: 2022-01-13

  Online published: 2022-08-08

Fold

Abstract

Objective To investigate the role of activin A, a member of transforming growth factor-β superfamily cytokine, in regulating migration and aerobic glycolysis of gastric cancer cells, and the prognostic value of the expression of its coding gene inhibin βA(INHBA) in survival of gastric cancer patients. Methods The gastric cells were first titrated with various concentration of activin A and the expression of pSmad2/3 was examined by Western blot(WB) to determine the concentration range of activin A used in the study. The effect of activin A on the migration of gastric cancer cells was monitored by transwell and wound healing assays. The lactate production and glucose uptake of gastric cancer cells were followed to evaluate the role of activin A on the regulation of aerobic glycolysis. The association between activin A and epithelial mesenchymal transformation(EMT)/glycolysis related genes was analyzed in the Cancer Genome Atlas (TCGA) gastric cancer database, and further validated by WB studies. The expression of INHBA in gastric cancer and normal mucosa tissue were analyzed in TCGA, Gene Expression Omnibus(GEO) and other publicly available databases to explore the association of INHBA expression level with patients’ survival. Results The activin A at 20 ng/mL sufficiently upregulate the level of pSmad2/3, and the concentration was thus used in the study. Activin A promoted migration and aerobic glycolysis of gastric cancer cells. There was a significant positive correlation between the expression of INHBA and several EMT related genes, hypoxia inducible factor-1 α(HIF1A), glucose transporter 3 (GLUT3) [SNAI1: r=0.47, P=0;SNAI2: r=0.51, P=0; VIM: r=0.37, P=2.1×10-14; matrix metalloproteinase(MMP)2: r=0.64, P=0; MMP9: r=0.27, P=2.8×10-8; HIF1A: r=0.45, P=0; SLC2A3: r=0.42, P=0]. After treatment with activin A, the expression of snail, slug, vimentin, MMP2 and GLUT3 increased significantly(P<0.05). The expression of INHBA in gastric cancer was significantly higher than that in normal gastric mucosa tissue, and the prognosis of patients with higher expression of INHBA was poor. Conclusions Activin A can promote migration and aerobic glycolysis, which might attribute to its upregulation of EMT related genes and GLUT3. High level of INHBA is indicative of prognosis for gastric cancer patients.

Key words： Gastric cancer; Activin A; Migration; Glycolysis

Cite this article

ZHAO Liqin, GUO Weijian, YU Nuoya, WU Junwei, ZHANG Jun . Effects of activin A on migration and aerobic glycolysis of gastric cancer cells[J]. Journal of Internal Medicine Concepts & Practice, 2022 , 17(04) : 317 -323 . DOI: 10.16138/j.1673-6087.2022.04.009

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
[3] Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia[J]. Nat Rev Dis Primers, 2018, 4: 17105.
[4] Morianos I, Papadopoulou G, Semitekolou M, et al. Activin-A in the regulation of immunity in health and disease[J]. J Autoimmun, 2019, 104: 102314.
[5] Ries A, Schelch K, Falch D, et al. Activin A: an emerging target for improving cancer treatment?[J]. Expert Opin Ther Targets, 2020, 24(10): 985-996.
[6] Thissen JP, Loumaye A. Role of activin A and myostatin in cancer cachexia[J]. Ann Endocrinol (Paris), 2013, 74(2): 79-81.
[7] Lee SJ, Lehar A, Meir JU, et al. Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight[J]. Proc Natl Acad Sci U S A, 2020, 117(38): 23942-23951.
[8] Ghosh AC, O’Connor MB. Systemic activin signaling independently regulates sugar homeostasis, cellular metabolism, and pH balance in Drosophila melanogaster[J]. Proc Natl Acad Sci U S A, 2014, 111(15): 5729-5734.
[9] Zhao L, Zhang J, Qu X, et al. Microsatellite instability-related ACVR2A mutations partially account for decreased lymph node metastasis in MSI-H gastric cancers[J]. Onco Targets Ther, 2020, 13: 3809-3821.
[10] Kaneda H, Arao T, Matsumoto K, et al. Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer[J]. Br J Cancer, 2011, 105(8): 1210-1217.
[11] Kim YI, Lee HJ, Khang I, et al. Selective inhibition of cell growth by activin in SNU-16 cells[J]. World J Gastroenterol, 2006, 12(19): 3000-3005.
[12] Dean M, Davis DA, Burdette JE. Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling[J]. Cancer Lett, 2017, 391: 114-124.
[13] Jung BH, Beck SE, Cabral J, et al. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin[J]. Gastroenterology, 2007, 132(2): 633-644.
[14] Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46.
[15] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation[J]. Science, 2009, 324(5930): 1029-1033.
[16] Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment[J]. Cancer Cell, 2012, 21(3): 309-322.
[17] Gill KS, Fernandes P, O’Donovan TR, et al. Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response[J]. Biochim Biophys Acta, 2016, 1866(1): 87-105.
[18] Huang Y, Chen ZC, Lu T, et al. HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 398.
[19] Chan DA, Sutphin PD, Nguyen P, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality[J]. Sci Transl Med, 2011, 3(94): 94ra70.
Options
Outlines

/

〈 〉